NCT02212236

Brief Summary

This Phase II trial aims to evaluate a new psychological intervention to alleviate distress during haematopoietic stem cell transplantation (HSCT) together with examining feasibility. HSCT is a complex procedure aimed at a range of haematological and autoimmune illnesses. Over 3,000 individuals undergo the procedure every year in the UK with substantial benefits. However, it is very costly, intensive, and has a range of debilitating side effects. Consequently, patients often experience considerable distress, which can impede recovery. A 90-minute, group-based intervention has been developed to address this need based on psychological theory of adjustment to illness-related difficulties. It is delivered by the transplant team and involves provision of information to foster more helpful perceptions about HSCT and facilitating more helpful coping with its difficulties. To evaluate the effectiveness of the intervention in alleviating distress, 60 patients about to undergo HSCT at two sites (Sheffield \& Nottingham) will be randomly allocated into two groups. Patients in the intervention group will receive the new intervention prior to transplantation together with treatment as usual (TAU) while patients in the control group will receive TAU alone. Participants and the researcher collecting the data will be blind to the allocation. Demographic and relevant clinical information will be recorded at the end of participation to ensure effectiveness of randomisation. For both groups, resilience, distress, coping, and procedure-related perceptions will be measured at four time points: (i) prior to the intervention/transplantation, (ii) day of transplant, (iii) two weeks following the transplant, and (iv) four weeks following the transplant. It is hypothesised that patients in the intervention group will experience higher resilience and lower distress compared to controls and that this difference will be mediated by procedure-related perceptions and coping. A subgroup of participants of those randomised to the group intervention will be invited to participate in a feedback interview at the end.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Sep 2014

Shorter than P25 for phase_2

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 4, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 8, 2014

Completed
24 days until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

October 28, 2015

Status Verified

October 1, 2015

Enrollment Period

1.1 years

First QC Date

August 4, 2014

Last Update Submit

October 27, 2015

Conditions

Keywords

DistressDepressionAnxietyStressCopingIllness perceptionsStem cell transplantationBone marrow transplantation

Outcome Measures

Primary Outcomes (4)

  • Depression Anxiety Stress Scales (DASS-21)

    Assesses presence of depression, anxiety, stress, and overall distress; 21 items, Likert-type.

    Baseline

  • Depression Anxiety Stress Scales (DASS-21)

    Assesses presence of depression, anxiety, stress, and overall distress; 21 items, Likert-type.

    Day 0 (transplant day)

  • Depression Anxiety Stress Scales (DASS-21)

    Assesses presence of depression, anxiety, stress, and overall distress; 21 items, Likert-type.

    Day 14

  • Depression Anxiety Stress Scales (DASS-21)

    Assesses presence of depression, anxiety, stress, and overall distress; 21 items, Likert-type.

    Day 28

Secondary Outcomes (12)

  • Brief Resilience Scale (BRS)

    Baseline

  • Brief Resilience Scale (BRS)

    Day 0 (transplant day)

  • Brief Resilience Scale (BRS)

    Day 14

  • Brief Resilience Scale (BRS)

    Day 28

  • Brief Coping with Problems Experienced scale (COPE)

    Baseline

  • +7 more secondary outcomes

Study Arms (2)

Psychological preparation + TAU

EXPERIMENTAL

TAU=treatment as usual

Other: Psychological preparation

Treatment as usual

NO INTERVENTION

Usual care including medication, nursing, and psychologist support.

Interventions

Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.

Psychological preparation + TAU

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients referred for HSCT as treatment for haematological malignancy
  • age of 18 years or older
  • sufficient command of the English language or access to suitable support to comprehend materials and participate in the group and data collection over the telephone
  • informed consent
  • permission will also be sought by the patient's Consultant Haematologist once clients have consented

You may not qualify if:

  • Consent withdrawn
  • Consultant Haematologist raises concern regarding participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Nottingham City Hospital

Nottingham, Nottinghamshire, NG5 1PB, United Kingdom

Location

Royal Hallamshire Hospital

Sheffield, South Yorkshire, S10 2JF, United Kingdom

Location

MeSH Terms

Conditions

DepressionAnxiety Disorders

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMental Disorders

Study Officials

  • Thomas Schröder, PhD

    University of Nottingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 4, 2014

First Posted

August 8, 2014

Study Start

September 1, 2014

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

October 28, 2015

Record last verified: 2015-10

Locations